Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | XENE |
---|---|---|
09:32 ET | 726 | 43.21 |
09:36 ET | 100 | 42.885 |
09:39 ET | 100 | 42.18 |
09:43 ET | 867 | 42.83 |
09:45 ET | 562 | 42.85 |
09:50 ET | 500 | 43.1137 |
10:03 ET | 200 | 43.01 |
10:06 ET | 200 | 43.06 |
10:12 ET | 774 | 43.11 |
10:17 ET | 623 | 43.13 |
10:19 ET | 100 | 43.14 |
10:32 ET | 208 | 43.066 |
10:35 ET | 100 | 42.98 |
10:39 ET | 200 | 43.025 |
10:51 ET | 200 | 42.89 |
10:57 ET | 900 | 42.925 |
11:00 ET | 1600 | 43 |
11:02 ET | 300 | 43.2 |
11:06 ET | 200 | 43.14 |
11:09 ET | 100 | 43.04 |
11:11 ET | 300 | 43 |
11:18 ET | 115 | 42.93 |
11:20 ET | 300 | 42.9 |
11:22 ET | 300 | 43.01 |
11:24 ET | 400 | 42.93 |
11:26 ET | 300 | 42.955 |
11:31 ET | 300 | 42.905 |
11:38 ET | 100 | 42.86 |
11:42 ET | 200 | 42.81 |
11:44 ET | 200 | 42.76 |
11:45 ET | 200 | 42.75 |
11:47 ET | 200 | 42.62 |
11:49 ET | 100 | 42.66 |
11:51 ET | 100 | 42.58 |
11:56 ET | 300 | 42.58 |
11:58 ET | 600 | 42.585 |
12:00 ET | 1200 | 42.6 |
12:02 ET | 100 | 42.675 |
12:05 ET | 200 | 42.57 |
12:07 ET | 300 | 42.5 |
12:09 ET | 100 | 42.47 |
12:12 ET | 200 | 42.47 |
12:18 ET | 100 | 42.475 |
12:20 ET | 100 | 42.4 |
12:21 ET | 100 | 42.395 |
12:23 ET | 300 | 42.445 |
12:32 ET | 300 | 42.51 |
12:34 ET | 200 | 42.58 |
12:36 ET | 100 | 42.67 |
12:38 ET | 877 | 42.64 |
12:39 ET | 100 | 42.64 |
12:43 ET | 100 | 42.685 |
12:45 ET | 100 | 42.715 |
12:48 ET | 100 | 42.685 |
12:50 ET | 300 | 42.69 |
12:54 ET | 300 | 42.62 |
12:56 ET | 100 | 42.635 |
12:57 ET | 200 | 42.59 |
12:59 ET | 200 | 42.6 |
01:01 ET | 398 | 42.465 |
01:08 ET | 300 | 42.37 |
01:10 ET | 200 | 42.38 |
01:12 ET | 1500 | 42.49 |
01:14 ET | 210 | 42.58 |
01:15 ET | 100 | 42.58 |
01:17 ET | 200 | 42.64 |
01:24 ET | 200 | 42.58 |
01:30 ET | 400 | 42.66 |
01:32 ET | 437 | 42.565 |
01:35 ET | 600 | 42.57 |
01:42 ET | 600 | 42.615 |
01:53 ET | 200 | 42.6 |
01:55 ET | 100 | 42.56 |
01:57 ET | 100 | 42.52 |
02:00 ET | 100 | 42.51 |
02:09 ET | 100 | 42.54 |
02:15 ET | 100 | 42.62 |
02:20 ET | 300 | 42.69 |
02:22 ET | 445 | 42.69 |
02:24 ET | 200 | 42.7 |
02:27 ET | 200 | 42.64 |
02:31 ET | 500 | 42.67 |
02:40 ET | 100 | 42.71 |
02:45 ET | 100 | 42.69 |
02:49 ET | 100 | 42.625 |
02:51 ET | 100 | 42.615 |
02:54 ET | 200 | 42.675 |
02:56 ET | 200 | 42.645 |
02:58 ET | 400 | 42.63 |
03:02 ET | 700 | 42.685 |
03:03 ET | 500 | 42.64 |
03:05 ET | 200 | 42.575 |
03:07 ET | 100 | 42.54 |
03:14 ET | 100 | 42.515 |
03:16 ET | 300 | 42.53 |
03:18 ET | 600 | 42.62 |
03:20 ET | 100 | 42.68 |
03:21 ET | 100 | 42.685 |
03:25 ET | 300 | 42.69 |
03:27 ET | 200 | 42.715 |
03:30 ET | 700 | 42.66 |
03:32 ET | 400 | 42.63 |
03:36 ET | 400 | 42.59 |
03:39 ET | 260 | 42.59 |
03:43 ET | 600 | 42.65 |
03:45 ET | 1213 | 42.65 |
03:48 ET | 100 | 42.63 |
03:50 ET | 500 | 42.61 |
03:52 ET | 1200 | 42.685 |
03:54 ET | 2320 | 42.84 |
03:56 ET | 2332 | 42.84 |
03:57 ET | 2582 | 42.9 |
03:59 ET | 3339 | 42.93 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Xenon Pharmaceuticals Inc | 3.3B | -15.7x | --- |
Janux Therapeutics Inc | 3.2B | -45.2x | --- |
SpringWorks Therapeutics Inc | 3.4B | -8.2x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
IDEAYA Biosciences Inc | 3.2B | -20.7x | --- |
Apogee Therapeutics Inc | 2.9B | -29.5x | --- |
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.2B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-2.73 |
Book Value | $12.31 |
P/E Ratio | -15.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.